Are Intensive Lipid-lowering Regimens an Optimal Economic Strategy in Patients with ACS? An Acute and Chronic Perspective

Roberta Ara; Rachid Rafia; Sue E Ward; Anthony S Wierzbicki; Tim M Reynolds; Angie Rees; Abdullah Pandor


Expert Rev Pharmacoeconomics Outcomes Res. 2009;9(5):423-433. 

In This Article

Expert Commentary

The existing economic evaluations show that an intensive lipid-lowering strategy is a cost-effective alternative to a standard-dose generic statin in individuals with ACS. While rosuvastatin 40 mg/day has been shown to be the optimal treatment using current prices for statins, when atorvastatin 80 mg/day is available in generic form, this may be the optimal treatment for this patient group. Simvastatin 80 mg/day should not be considered an alternative owing to the adverse safety profile and limited additional benefits. The cost–effectiveness of the alternative treatments should be revisited and updated when data from clinical end point studies are available for rosuvastatin. Any future economic evaluations should endeavor to include sensitivity analyses exploring the effect of different adherence levels to the more potent doses and the economics should be revisited once this data becomes available.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.